Pristiq: Targeted Serotonin-Norepinephrine Reuptake Inhibition
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.09 | $62.78 (0%) | 🛒 Add to cart |
| 40 | $2.00 | $83.71 $79.98 (4%) | 🛒 Add to cart |
| 60 | $1.92 | $125.56 $115.24 (8%) | 🛒 Add to cart |
| 90 | $1.85 | $188.34 $166.84 (11%) | 🛒 Add to cart |
| 120 | $1.83 | $251.12 $219.30 (13%) | 🛒 Add to cart |
| 180 | $1.80 | $376.68 $324.22 (14%) | 🛒 Add to cart |
| 270 | $1.79
Best per pill | $565.02 $482.46 (15%) | 🛒 Add to cart |
Synonyms | |||
Pristiq (desvenlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD) in adults. As the major active metabolite of venlafaxine, it offers a refined pharmacological profile with dual monoaminergic activity. This medication works by increasing the levels of serotonin and norepinephrine in the brain, two neurotransmitters critically involved in mood regulation. Clinical studies support its efficacy in reducing depressive symptoms and improving functional outcomes. Proper diagnosis and ongoing medical supervision are essential throughout treatment.
Features
- Contains desvenlafaxine succinate, a potent SNRI
- Available in 25 mg, 50 mg, and 100 mg extended-release tablets
- Once-daily oral administration
- Bioavailability of approximately 80% and not affected by food
- Median time to peak plasma concentration is 7.5 hours post-dose
- Steady-state plasma concentrations achieved within 4–5 days
- Primarily metabolized via conjugation and CYP3A4 to a minor extent
- Elimination half-life of approximately 11 hours
Benefits
- Reduces core symptoms of major depressive disorder, including low mood and anhedonia
- May improve energy, concentration, and overall daily function
- Dual reuptake inhibition targets a broader range of neurotransmitter systems than SSRIs alone
- Once-daily dosing supports adherence and consistent pharmacokinetics
- Extended-release formulation minimizes peak-trough fluctuations and may reduce side effects
- Demonstrated efficacy in adult populations across multiple randomized controlled trials
Common use
Pristiq is indicated for the treatment of major depressive disorder (MDD). It is prescribed for adults experiencing episodes of depression characterized by persistent sadness, loss of interest or pleasure, changes in appetite or sleep, fatigue, and difficulty concentrating. Treatment is typically initiated after a comprehensive psychiatric assessment. It is not approved for use in pediatric patients.
Dosage and direction
The recommended starting dose for Pristiq is 50 mg once daily, taken orally with or without food. Tablets should be swallowed whole and not crushed, chewed, or dissolved. Dosage may be adjusted based on individual patient response and tolerability, though increases beyond 50 mg per day have not shown additional benefit in clinical studies and may increase the incidence of adverse reactions. For patients with hepatic or severe renal impairment, a dose reduction is recommended. Abrupt discontinuation should be avoided; a gradual taper is advised under medical supervision to minimize withdrawal symptoms.
Precautions
Patients should be monitored for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of therapy or after dose changes. Pristiq may increase the risk of bleeding; caution is advised in patients taking anticoagulants or with inherent bleeding risk. Use with caution in patients with a history of mania/hypomania, seizures, or angle-closure glaucoma. Blood pressure should be monitored regularly due to the potential for increases. Discontinuation symptoms including dizziness, nausea, and anxiety may occur upon abrupt cessation.
Contraindications
Pristiq is contraindicated in patients with known hypersensitivity to desvenlafaxine, venlafaxine, or any excipients in the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome; at least 14 days should elapse between discontinuing an MAOI and initiation of Pristiq, and vice versa.
Possible side effects
Common adverse reactions (≥5% and twice the rate of placebo) include nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders. Less frequently, elevated blood pressure, increased cholesterol, and abnormal bleeding have been observed. Serotonin syndrome, although rare, is a serious potential side effect, particularly when used with other serotonergic drugs.
Drug interaction
Concomitant use with MAOIs is contraindicated. Use with other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, tramadol) increases the risk of serotonin syndrome. Drugs that interfere with hemostasis (NSAIDs, aspirin, warfarin) may increase the risk of bleeding. Strong CYP3A4 inhibitors may increase desvenlafaxine exposure. Pristiq may reduce the efficacy of tamoxifen by inhibiting its conversion to endoxifen.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is closer to the time of the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling of doses is not recommended.
Overdose
Symptoms of overdose may include serotonin syndrome, tachycardia, changes in level of consciousness, mydriasis, seizures, and vomiting. There is no specific antidote. Management involves supportive care and symptomatic treatment. Gastric lavage or administration of activated charcoal may be considered if presented early. Ensure adequate airway and monitor cardiac and vital signs.
Storage
Store at room temperature, 20°–25°C (68°–77°F), with excursions permitted between 15°–30°C (59°–86°F). Keep in the original container, tightly closed, and protect from moisture. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with any questions regarding a medical condition or before starting any new treatment. Do not disregard or delay seeking professional medical advice based on information contained herein.
Reviews
Clinical trials and post-marketing surveillance indicate that Pristiq is generally well-tolerated and effective for many patients with MDD. Individual responses vary, and some patients report significant improvement in mood and functionality, while others may experience side effects that limit tolerability. Long-term adherence often depends on effective management of side effects and regular follow-up with a prescribing clinician.